News Boehringer collaborates with Autifony on schizophrenia drug Deal could be worth 627.5 million euros
News Gilead could make a move for Galapagos within weeks The share price of Belgium-Dutch biotech Galapagos is rising thanks to renewed speculation that Gilead may be poised to acquire it.
News After more encouraging data, Ablynx to file first drug with ... New trial data will be included in US and EU filings
Views & Analysis How can the UK improve in clinical research? A biotech persp... The UK is a great place for early-stage research – but NHS red tape and market access remain major barriers.
News Apitope announces IPO to fund MS drug development Biotech Apitope plans to float on the Brussels stock exchange to raise funds to develop a potential new MS drug.
Views & Analysis European biotech round-up: Ablynx’s big break and more European biotech: a mixture of encouraging clinical trials and new funding lift the sector.
News NICE backs first targeted therapy for ALK+ lung cancer Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.